Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course.
Muri J, Cecchinato V, Cavalli A, Shanbhag AA, Matkovic M, Biggiogero M, Maida PA, Moritz J, Toscano C, Ghovehoud E, Furlan R, Barbic F, Voza A, Nadai G, Cervia C, Zurbuchen Y, Taeschler P, Murray LA, Danelon-Sargenti G, Moro S, Gong T, Piffaretti P, Bianchini F, Crivelli V, Podešvová L, Pedotti M, Jarrossay D, Sgrignani J, Thelen S, Uhr M, Bernasconi E, Rauch A, Manzo A, Ciurea A, Rocchi MBL, Varani L, Moser B, Bottazzi B, Thelen M, Fallon BA, Boyman O, Mantovani A, Garzoni C, Franzetti-Pellanda A, Uguccioni M, Robbiani DF.
Muri J, et al. Among authors: manzo a.
bioRxiv [Preprint]. 2022 Nov 27:2022.05.23.493121. doi: 10.1101/2022.05.23.493121.
bioRxiv. 2022.
PMID: 35664993
Free PMC article.
Updated.
Preprint.